Journal
BIOCHEMICAL SOCIETY TRANSACTIONS
Volume 36, Issue -, Pages 1414-1417Publisher
PORTLAND PRESS LTD
DOI: 10.1042/BST0361414
Keywords
helix mimetic; inhibitor; medicinal chemistry; protein-protein interaction; rational design
Categories
Funding
- National Institutes of Health [GM69850]
Ask authors/readers for more resources
The inhibition of protein-protein interactions using small molecules is a viable approach for the treatment of a range of pathological conditions that result from a malfunctioning of these interactions. Our strategy for the design of such agents involves the mimicry of side-chain residues on one face of the a-helix; these residues frequently play a key role in mediating protein-protein interactions. The first-generation terphenyl scaffold, with a 3,2',2-substitution pattern, is able to successfully mimic key helix residues and disrupt therapeutically relevant interactions, including the BCI-X-L-Bak and the pS3-hDM2 (human double minute 2) interactions that are implicated in cancer. The second- and third-generation scaffolds have resulted in greater synthetic accessibility and more drug-like character in these molecules.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available